• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Anthim (obiltoxaximab)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Anthim (obiltoxaximab)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Anthim (obiltoxaximab) is a monoclonal antibody that binds the PA of B. anthracis.

    Anthim is specifically indicated for use in adult and pediatric patients for the treatment of inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs and for prophylaxis of inhalational anthrax due to B. anthracis when alternative therapies are not available or not appropriate.

    Anthim is supplied as an injection for intravenous administration. The recommended dose is as follows:

    Adults:

    • Pre-medicate with diphenhydramine prior to administering Anthim
    • Dilute the injection in 0.9% Sodium Chloride Injection, USP, before administering as an intravenous infusion
    • Administer a single dose of 16 mg/kg intravenously over 90 minutes (1 hour and 30 minutes)
    • See drug label for administration in adult patients weighing less than 40 kg.

    Pediatrics:

    • Pre-medicate with diphenhydramine prior to administering Anthim
    • Dilute the injection in 0.9% Sodium Chloride Injection, USP, before administering as an intravenous infusion
    • The recommended dose for pediatric patients is based on weight: 
    • Body Weight: Greater than 40 kg Dose: 6 mg/kg
    • Body Weight: Greater than 15 kg to 40 kg Dose: 24 mg/kg
    • Body Weight: Less than or equal to 15 kg Dose: 32 mg/kg
    • Administer the recommended dose of Anthim intravenously over 90 minutes (1 hour and 30 minutes) 

    Clinical Results

    FDA Approval

    As it is not feasible or ethical to conduct controlled clinical trials in humans with inhalational anthrax, the efficacy of Anthim for the treatment of inhalational anthrax was based on efficacy studies in NZW rabbits and cynomolgus macaques. Anthim monotherapy administered as a single 16 mg/kg IV dose for the treatment of inhalational anthrax disease resulted in statistically significant improvement in survival relative to placebo in two studies for each species.  Anthim administered in combination with antibacterial drugs (levofloxacin, ciprofloxacin and doxycycline) for the treatment of systemic inhalational anthrax disease resulted in higher survival outcomes than antibacterial therapy alone in multiple studies where Anthim and antibacterial therapy was given at various doses and treatment times.  Anthim administered as prophylaxis resulted in higher survival outcomes compared to placebo in multiple studies where treatment was given at various doses and treatment times. 

    Side Effects

    Adverse effects associated with the use of Anthim may include, but are not limited to, the following:

    • headache
    • pruritus
    • infections of the upper respiratory tract
    • cough
    • vessel puncture site bruise
    • infusion site swelling
    • nasal congestion
    • infusion site pain
    • urticaria
    • pain in extremity

    Anthim comes with a black box warning of hypersensitivity reactions, including anaphylaxis, have been reported during Anthim infusion

    Mechanism of Action

    Anthim (obiltoxaximab) is a monoclonal antibody that binds free PA with an affinity equilibrium dissociation constant (Kd) of 0.33 nM. Obiltoxaximab inhibits the binding of PA to its cellular receptors, preventing the intracellular entry of the anthrax lethal factor and edema factor, the enzymatic toxin components responsible for the pathogenic effects of anthrax toxin. 

    Additional Information

    For additional information regarding Anthim or anthrax infection, please visit http://anthim.com/

    Approval Date: 2016-03-01
    Company Name: Elusys Therapeutics
    Back to Listings

    Upcoming Events

    • 26Jan

      Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

    • 27Jan

      Medical Device Clinical Trials in China: Latest Regulatory Developments

    • 11Feb

      Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

    • 23Mar

      Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

    • 26Apr

      MAGI's Clinical Research vConference — Spring 2021

    Featured Products

    • Regenerative Medicine – Steps to Accelerate Development : PDF

      Regenerative Medicine: Steps to Accelerate Development

    • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

      Clinical Trial Agreements: A Guide to Key Words and Phrases

    Featured Stories

    • Resources-360x240.png

      Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

    • FocusinRed-360x240.png

      Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

    • VaccinewithNeedle-360x240.png

      2021 Vaccine Industry Will Continue to be Dominated by COVID-19 Trials, Experts Say

    • Dominate-360x240.png

      COVID-19, Oncology, CNS and Infectious Disease Trials Will Dominate in 2021, Survey Predicts

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing